Haleon plc
NYSE•HLN
CEO: Mr. Brian James McNamara
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Listing Date: 2022-07-25
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
Contact Information
The Heights, Building 5, First Floor, Weybridge, KT13 0NY, United Kingdom
44-1932-822000
Market Cap
$40.31B
P/E (TTM)
29.4
26.1
Dividend Yield
2.1%
52W High
$11.28
52W Low
$8.65
52W Range
Rank34Top 27.8%
4.7
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Average • 4.7 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2020-2025
Deep Research
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data